FDA pauses vaccination with J&J vaccine after six cases of blood clot
U.S. CDC and FDA called for a pause in the J&J’s vaccine use following the emergence of a rare blood clotting disorder in six recipients.
Pharmaceuticals, Biotechnology and Life Sciences
U.S. CDC and FDA called for a pause in the J&J’s vaccine use following the emergence of a rare blood clotting disorder in six recipients.
DUBLIN–(BUSINESS WIRE)–The “Global Preventive Vaccines Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s…
First DARZALEX combination regimen being pursued as frontline treatment option for transplant eligible patients with multiple myeloma BEERSE, Belgium–(BUSINESS WIRE)–The…
Idorsia said Monday Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has exercised its option to enter…
Janssen Research & Development, said Wednesday the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for Xarelto (rivaroxaban).
Johnson & Johnson is seizing upon a U.S. Supreme Court ruling from Monday limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer.
A county in New York state has sued Purdue Pharma LP, Johnson & Johnson <JNJ.N> and other drugmakers, accusing them of engaging in fraudulent marketing that played down the risks of prescription opioid painkillers, leading to a drug epidemic.
Johnson & Johnson said its $30 billion tender offer for Swiss biotechnology company Actelion was successful, with the price of the offer being 280 per share for Actelion.
Biocartis has today strenghten its collaboration with two companies; J&J’s Jansen and Amgen, as it has submitted 510(k) its diagnostics…
Johnson&Johnson has decreased its shareholding in Biocartis, the Belgian drugmaker said on Wednesday. In a disclosure of a transparency notification,…